[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dexcom Inc (DXCM)

Dexcom Inc (DXCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

DexCom's Margin Guidance Held Steady Despite Growth Acceleration—Confidence or Caution Ahead?

Dexcom Inc (DXCM) reports second-quarter 2026 earnings after market close on July 30, 2026, with analysts expecting the continuous glucose monitoring leader to deliver $0.61 per share on continued momentum in its core diabetes management business. The central question: can Dexcom sustain the impressive margin expansion and international growth trajectory that drove a 19% earnings beat last quarter, or will heightened competition and geopolitical cost pressures begin to weigh on results?

Dexcom Inc develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management, serving both Type 1 and Type 2 diabetes patients across U.S. and international markets. The company has emerged as a...

Fundamentals

See More
  • Market Capitalization, $K 28,994,496
  • Shares Outstanding, K 385,873
  • Annual Sales, $ 4,662 M
  • Annual Income, $ 836,300 K
  • EBIT $ 1,033 M
  • EBITDA $ 1,285 M
  • 60-Month Beta 1.45
  • Price/Sales 6.20
  • Price/Cash Flow 27.03
  • Price/Book 9.77

Options Overview Details

View History
  • Implied Volatility 53.34% (+0.36%)
  • Historical Volatility 40.58%
  • IV Percentile 69%
  • IV Rank 51.34%
  • IV High 77.57% on 10/30/25
  • IV Low 27.78% on 08/05/25
  • Expected Move (DTE 1) 4.97 (6.74%)
  • Put/Call Vol Ratio 2.79
  • Today's Volume 22,402
  • Volume Avg (30-Day) 2,899
  • Put/Call OI Ratio 0.97
  • Today's Open Interest 81,309
  • Open Int (30-Day) 80,167
  • Expected Range 68.85 to 78.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.61
  • Number of Estimates 9
  • High Estimate $0.64
  • Low Estimate $0.58
  • Prior Year $0.48
  • Growth Rate Est. (year over year) +27.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.87 +8.86%
on 07/01/26
79.15 -6.66%
on 07/16/26
+6.53 (+9.70%)
since 06/30/26
3-Month
57.65 +28.14%
on 05/14/26
79.15 -6.66%
on 07/16/26
+14.33 (+24.06%)
since 04/30/26
52-Week
54.11 +36.54%
on 11/07/25
87.00 -15.08%
on 07/31/25
-15.18 (-17.04%)
since 07/30/25

Most Recent Stories

More News
DexCom's Margin Guidance Held Steady Despite Growth Acceleration—Confidence or Caution Ahead?

Barchart Research What to Expect from DXCM Earnings DXCM Generated July 29, 2026 Current Price $75.14 EPS Estimate $$0.61 Consensus Rating Strong Buy Average Move 12.40% DexCom's Margin Guidance Held Steady...

DXCM : 74.54 (-0.80%)
DexCom Earnings: What To Look For From DXCM

DexCom Earnings: What To Look For From DXCM

DXCM : 74.54 (-0.80%)
Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company’s long-term investors. ...

DXCM : 74.54 (-0.80%)
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program

Participation advances the company’s vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment

DXCM : 74.54 (-0.80%)
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END

AVAI : 0.1148 (-11.69%)
TNDM : 19.01 (+2.26%)
NVO : 51.58 (-0.62%)
DXCM : 74.54 (-0.80%)
SNY : 42.89 (-4.37%)
2 Cash-Heavy Stocks on Our Buy List and 1 We Avoid

2 Cash-Heavy Stocks on Our Buy List and 1 We Avoid

SNOW : 297.95 (+5.32%)
WRBY : 26.00 (-0.12%)
DXCM : 74.54 (-0.80%)
1 Mid-Cap Stock to Target This Week and 2 We Find Risky

1 Mid-Cap Stock to Target This Week and 2 We Find Risky

AFG : 141.62 (-1.32%)
DXCM : 74.54 (-0.80%)
BIIB : 207.96 (-0.61%)
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

Dexcom G7 15 Day is the longest‑lasting and most accurate 1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days ...

DXCM : 74.54 (-0.80%)
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call...

DXCM : 74.54 (-0.80%)
Earnings Preview: What To Expect From DexCom's Report

DexCom is expected to announce its second-quarter earnings soon, and Wall Street expects the company’s EPS to increase by a double-digit percentage.

XLV : 163.48 (-1.66%)
$SPX : 7,441.86 (+1.72%)
DXCM : 74.54 (-0.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of...

See More

Key Turning Points

3rd Resistance Point 78.97
2nd Resistance Point 77.53
1st Resistance Point 76.33
Last Price 74.54
1st Support Level 73.69
2nd Support Level 72.25
3rd Support Level 71.06

See More

52-Week High 87.00
Last Price 74.54
Fibonacci 61.8% 74.44
Fibonacci 50% 70.56
Fibonacci 38.2% 66.67
52-Week Low 54.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.